Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older.
- People with a type of lung cancer called EGFR-mutated non-small cell lung cancer (NSCLC) that has either spread locally (stage IIIB) or spread to other parts of the body (stage IV).
- People who have previously been confirmed to have a specific gene change (EGFR Ex19del, L858R, or T790M mutation) and have been treated with a drug called Osimertinib, where imaging scans show the cancer has grown only slowly — meaning the disease was controlled for more than 6 months, the tumour has increased only slightly, and symptoms are mild or absent.
- People who are planning to receive a higher dose (160mg, double dose) of a cancer treatment drug called Furmonertinib.
- People who have at least one tumour that has not previously been treated with radiation, can be clearly measured, and is large enough to meet specific size requirements on a chest CT or PET-CT scan (confirm with trial site for exact size details).
- People whose second biopsy after their cancer stopped responding to treatment did not find any other treatable genetic targets.
- People whose expected survival is more than 3 months.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have already been treated with Furmonertinib.
- People who are planning to use a cancer treatment other than Furmonertinib in the near future.
- People for whom Furmonertinib is medically unsuitable or contraindicated (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-23-68757791
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
ORR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.